TRACON Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of TRACON Pharmaceuticals generated cash of $3,676,000, which is more than the previous year. Cash used in financing activities reached the amount of -$12,539,000 last year. Net change in cash is therefore -$8,863,000.
Cash Flow
| 2014 | 1.75M | -70K | 31.03M |
|---|---|---|---|
| 2015 | -19.16M | -10.91M | 36.45M |
| 2016 | -27.15M | 2.07M | 19.41M |
| 2017 | -13.24M | 3.67M | 3.32M |
| 2018 | -30.78M | -8.86M | 35.32M |
| 2019 | -23.65M | 14.02M | 906K |
| 2020 | -17.04M | -4.00M | 36.76M |
| 2021 | -22.57M | 3.95M | 10.56M |
| 2022 | -26.23M | -17K | 19.68M |
| 2023 | 3.67M | 0 | -12.53M |
TCON Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 17.5M | 24.07M | 32.13M | 16.41M | 25.13M | 29.46M | 35.71M | 41.37M | 35M | 2.27M |
Operating activities | ||||||||||
Net income | -3.58M | -29.13M | -28.66M | -16.77M | -22.67M | -34.95M | -19.10M | -27.00M | -24.41M | -6.80M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 0 | 70K | -59K | -13K | 16K | 28K | 48K | 94K | 51K | 15K |
Stock-based compensation expense | 1.96M | 2.04M | 1.77M | 1.03M | 1.62M | 2.66M | 3.19M | 3.08M | 2.08M | 271K |
| Deferred income tax benefit | 1.96M | 2.04M | 1.77M | 1.03M | 1.62M | 2.66M | 3.19M | 3.08M | 2.08M | 271K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -1.39M | -233K | 4.68M | -1.87M | -3.42M | 4.14M | 776K | -2.20M | 6.14M | 2.67M |
Cash generated by operating activities | 3.67M | -26.23M | -22.57M | -17.04M | -23.65M | -30.78M | -13.24M | -27.15M | -19.16M | 1.75M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | -3.99M | -4.98M | -32.86M | -13.99M | -17.50M | -12.79M | 0 |
Investments In Property Plant And Equipment | 0 | -17K | -48K | -5K | 0 | 0 | -39K | -3K | -127K | -70K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | -17K | 3.95M | -4.00M | 14.02M | -8.86M | 3.67M | 2.07M | -10.91M | -70K |
Financing activities | ||||||||||
Common Stock Issued | 7.91M | 7.87M | 13.36M | 38.16M | 2.29M | 36.45M | 4.14M | 21.41M | 36.38M | 25.65M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -20.5M | 11.71M | -2.8M | -1.4M | -1.4M | -8.32M | -850K | -2M | 70K | -920K |
Cash used in financing activities | -12.53M | 19.68M | 10.56M | 36.76M | 906K | 35.32M | 3.32M | 19.41M | 36.45M | 31.03M |
Net Change In Cash | -8.86M | -6.57M | -8.05M | 15.71M | -8.72M | -4.33M | -6.24M | -5.66M | 6.37M | 32.72M |
Cash at end of period | 8.63M | 17.5M | 24.07M | 32.13M | 16.41M | 25.13M | 29.46M | 35.71M | 41.37M | 35M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |